Pharmaceutical MDL-2243 Closed • NJ

Fosamax Bone Injury Lawsuit

IN RE: Fosamax (Alendronate Sodium) Products Liability Litigation (No. II)

557
Pending Actions
1,293
Total Actions Filed
57%
Resolution Rate
Active
Status
Updated 2026-05-01

Case Resolution Progress

This long-running pharmaceutical MDL shows active case resolution. After a surge of new cases in mid-2025, 415 cases have been resolved from the peak through settlements and dispositions.

Jan 25
5
Feb 25
5
Mar 25
5
Apr 25
5
May 25
950
Jun 25
971
Jul 25
972
Aug 25
972
Sep 25
966
Oct 25
846
Nov 25
845
Dec 25
580
Jan 26
572
Feb 26
564
Mar 26
561
Apr 26
561
May 26
557

Source: JPML MDL Statistics Reports, January 2025-May 2026

Overview

The Fosamax (Alendronate Sodium) MDL consolidates lawsuits against Merck involving the osteoporosis drug Fosamax. Plaintiffs allege the medication causes atypical femur fractures (thigh bone breaks), osteonecrosis of the jaw (jawbone death), and other serious bone injuries.

As of 2026-05-01, there are 557 pending actions out of 1,293 total actions filed, representing a 57% resolution rate.

Who May Qualify

Eligibility for this MDL typically depends on factors such as:

  • History of taking Fosamax (alendronate sodium) for osteoporosis
  • Diagnosis of atypical femur fracture or osteonecrosis of the jaw
  • Medical records documenting Fosamax use and subsequent bone injury

Key Information

Assigned Judge

Karen M. Williams (U.S. District Judge)

District Court

District of New Jersey

MDL Number

MDL-2243

Category

Pharmaceutical

Attorney Advertising. The information on this page is for general informational purposes only and does not constitute legal advice. No attorney-client relationship is formed by reading this content. Results in MDL cases vary widely; past results do not guarantee future outcomes. If you believe you have a legal claim, consult a licensed attorney in your jurisdiction.